Status:
COMPLETED
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients
Lead Sponsor:
Kibow Pharma
Collaborating Sponsors:
Thomas Jefferson University
Conditions:
Chronic Kidney Failure
Eligibility:
All Genders
18-75 years
Brief Summary
A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "Enteric DialysisTM". However, it is also refe...
Detailed Description
Probiotics are increasingly utilized clinically. As their safety and health benefits are established, it is reasonable to anticipate that probiotic bacteria will be incorporated into a growing number ...
Eligibility Criteria
Inclusion
- Age 18 to 75 years
- CKD Stages 3 and 4 as documented by prior medical history
- Serum Creatinine \>2.5 mg/dL
- Stable and on CKD status 3 and 4 at least for a year or more
Exclusion
- Pregnant or nursing women
- Refusal to sign the informed consent form
- Documented to have HIV/AIDS/Liver disease
- Active dependency on drugs or alcohol
- Any non-related medical, debilitating disease/disorder that would interfere with adherence to this study
- Currently on anticoagulant therapy
Key Trial Info
Start Date :
July 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01450657
Start Date
July 1 2011
End Date
October 1 2012
Last Update
August 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107